On May 4, 1953, Aju Pharm started operations to help patients
suffering from tuberculosis amidst the ruins of the Korean War.
Aju Pharm (formerly known as Asia Pharmaceutical) founded by the late Kim Kwang-nam in Bosu-dong, Busan.
The first domestic production of antituberculosis drug, Asiazit, is manufactured.
Headquarters moved to Yongsan-gu, Seoul.
New headquarters and factory completed in Shinrim-dong, Guro-gu, Seoul.
Releases Compral, an antipyretic analgesic agent, manufactured through a collaborative alliance with Bayer.
Launch of Abomin, a medication which provides relief from vomiting of pregnancy and motion sickness, manufactured in partnership with the British company, May & Baker.
Releases antituberculosis drug, Almiaspas, in partnership with the Japanese company, Tanabe Pharma.
Expansion of injection equipment production facility.
Release of antituberculosis drug, Aipisit, in cooperation with Tanabe Pharma.
Presidential commendation awarded for Aju Pharm’s efforts to eliminate tuberculosis.
Introduces for the first time in Korea, Rabonal-M, an injectable general anesthetic with a short half-life, in cooperation with Tanabe Pharma.
Construction of pharmaceutical grade raw material plant completed.
Commendation from the Ministry of Health & Welfare for export of raw materials.
Successfully synthesizes acetaminophen, an antipyretic analgesic; export sales reach $0.3 million.
Commendation from the Ministry of Health & Welfare for efforts to increase export of goods.
Commendation from the Ministry of Health & Welfare.
Commendation from the Ministry of Trade, Industry and Energy.
The current CEO, Kim Joong-kil, is named president of Aju Pharm after the passing of the founder, Kim Kwang-nam.
Aju Pharm is selected as one of the leading small and medium-sized companies by the Ministry of Science and Technology.
Terminates production of pharmaceutical grade raw materials to concentrate efforts on the manufacturing and sale of finished drugs.
Releases Vesseldue-F Cap, an antihyperlipidemic agent, through technical cooperation with the Italian company, Alfa Wassermann.
Construction of headquarters and KGMP plant in Pyeongtaek completed.
Research and Development center established.
Produces Profenid for Rhone-Poulenc Rorer Pharmaceuticals.
Produce Norcuron and Deca-Durabolin for Organon.
Launches Zhengchangsheng through technical cooperation with Jeil Pharmaceutical China.
Releases Vesseldue-F, an antithrombotic agent, through technical cooperation with Alfa Wassermann.
Launches Uro-vaxom, a therapeutic treatment for chronic or recurrent urinary tract infections, in collaboration with the Swiss company, OM Pharma (now known as Vifor Pharma).
Produces Paoscle for Toril corporation of Japan.
Launches Bronchovaxom Cap, a COPD medication, in collaboration with OM Pharma (Vifor Pharma).
Launching of Olea, Aju Pharm’s consumer health brand.
A new plant dedicated to manufacturing cephalosporin antibiotics begins production.
Aju Pharm launches its Medical Devices business.
Company name changed from Asia Pharm to Aju Pharm.
Aju Pharm is accredited by the Pharmaceuticals and Medical Device Agency of Japan as an appropriate foreign manufacturer meeting PMDA’s guidelines.
Technology Transfer Agreement for asthma treatment research signed with Biomedical Center of Korea Research Institute of Bioscience and Biotechnology.
Receives a presidential commendation for reaching $1.0 million in exports.
Technology Transfer Agreement and Academic-Industry Partnership Agreement signed with Dongguk University’s Medical Device Development Center.
Establishes Regencare, a joint venture with Bestian Medical Center, a hospital specializing in burn therapy.
Construction of Medical Device plant in Bundang completed.
Construction of dedicated tablet and capsule manufacturing plant completed.